Pyrimidine amide compounds as PGDS inhibitors

Details for Australian Patent Application No. 2006299428 (hide)

Owner Aventis Pharmaceuticals Inc.

Inventors Lu, Jinqi; Ma, Liang; Jiang, John Ziqi; Sabol, Jeffrey Stephen; Aldous, Suzanne C.; Munson, Harry Randall; Thurairatnam, Sukanthini; Mu, Lan; Vandeusen, Christopher Loren

Agent Watermark

Pub. Number AU-B-2006299428

PCT Pub. Number WO2007/041634

Priority 60/723,570 04.10.05 US

Filing date 4 October 2006

Wipo publication date 12 April 2007

Acceptance publication date 26 April 2012

International Classifications

C07D 239/28 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 11/00 (2006.01) Drugs for disorders of the respiratory system

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/12 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

Event Publications

1 May 2008 PCT application entered the National Phase

  PCT publication WO2007/041634 Priority application(s): WO2007/041634

26 April 2012 Application Accepted

  Published as AU-B-2006299428

23 August 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006299429-Fc variants with optimized Fc receptor binding properties

2006299426-Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection